Fukuyama Congenital Muscular Dystrophy: Clinical Aspects
Fig. 1.1 Facial appearance changes with age in a girl with FCMD; images were obtained at 7 months (A), at 1 year and 5 months (B), and at 8 years…
Toward Regenerative Medicine for Muscular Dystrophies
© Springer Japan 2016Shin’ichi Takeda, Yuko Miyagoe-Suzuki and Madoka Mori-Yoshimura (eds.)Translational Research in Muscular Dystrophy10.1007/978-4-431-55678-7_7 7. Toward Regenerative Medicine for Muscular Dystrophies Lessons from Regeneration Processes Akiyoshi Uezumi1 and So-ichiro Fukada2 (1) Division for Therapies Against Intractable Diseases,…
Targeting the Type I TGF-β Receptor for Treating Caveolin-3-Deficient Autosomal Dominant Limb-Girdle Muscular Dystrophy Type 1C and Muscle Wasting Disorders
Fig. 5.1 Caveolins regulate myostatin and related TGF-β signaling at the type I receptor level. (a) Schematic representation of myostatin and related TGF-β signaling and caveolin-3. Type I serine/threonine receptor…
